ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the subsidy status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the subsidy recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Apr 2022
Last Updated on 12 Jul 2022
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Olaparib 100 mg and 150 mg tablets for treating advanced ovarian cancer in line with specific clinical criteria.

Subsidy status

Olaparib 100 mg and 150 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) with effect from 1 September 2022 for the following indications:
  • As maintenance monotherapy for adults with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Treatment should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months;
  • In combination with bevacizumab biosimilar (subsidised brand) as maintenance treatment of adults with advanced homologous recombination deficiency (HRD) positive high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab biosimilar. Treatment with olaparib should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months; and
  • As maintenance monotherapy for patients with platinum-sensitive relapsed BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Patients must not have received prior treatment with a PARP inhibitor for ovarian cancer. Treatment should be continued until disease progression or unacceptable toxicity.
MAF assistance does not apply to olaparib 50 mg capsules, or to any formulations or strengths of bevacizumab reference biologic (Avastin) or niraparib.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.


PARP inhibitors and bevacizumab for treating advanced ovarian cancer (12 Jul 22) PES Treatments for advanced ovarian cancer (Published 1 April 2022)